Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: A systematic review and meta-analysis

Clinical Colorectal Cancer

Volumn 10, Issue 1, 2011, Pages 63-69

  Lin, Albert Y ^a,b   Buckley, Nicholas S ^c   Lu, An Ting T ^a   Kouzminova, Natalia B ^a   Salpeter, Shelley R ^a,b  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Anti EGFR treatment; Panitumumab

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; K RAS PROTEIN; PANITUMUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; RAS PROTEIN;

ADVANCED CANCER; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; GENE MUTATION; HUMAN; MEDLINE; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; COLORECTAL TUMOR; CONFIDENCE INTERVAL; GENETICS; KAPLAN MEIER METHOD; META ANALYSIS; METABOLISM; MORTALITY; PATHOLOGY; TREATMENT FAILURE; UNITED STATES;

ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; DISEASE PROGRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT FAILURE; UNITED STATES;

EID: 80053408030     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.3816/CCC.2011.n.009     Document Type: Article

References (47)

1. SD Markowitz, MM Bertagnolli Molecular origins of cancer: Molecular basis of colorectal cancer N Engl J Med 361 2009 2449 2460
2. FDA Press Release. FDA approves Erbitux for colorectal cancer: US. Food and Drug Administration, 2004.
3. FDA Press Release. FDA approves Vectibix for colorectal cancer: US Food and Drug Administration, 2006.
4. HJ Lenz, E Van Cutsem, S Khambata-Ford et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines J Clin Oncol 24 2006 4914 4921 (Pubitemid 46630920)
5. LB Saltz, NJ Meropol, PJ Loehrer Sr. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 2004 1201 1208 (Pubitemid 41079832)
6. T Fojo, C Grady How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question J Natl Cancer Inst 101 2009 1044 1048
7. TP Plesec, JL Hunt KRAS mutation testing in colorectal cancer Adv Anat Pathol 16 2009 196 203
8. A Lievre, JB Bachet, D Le Corre et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 2006 3992 3995
9. F Di Fiore, F Blanchard, F Charbonnier et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy Br J Cancer 96 2007 1166 1169 (Pubitemid 46625066)
10. S Khambata-Ford, CR Garrett, NJ Meropol et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab J Clin Oncol 25 2007 3230 3237 (Pubitemid 47325606)
11. CJ Allegra, JM Jessup, MR Somerfield et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy J Clin Oncol 27 2009 2091 2096
12. H Spiro Cetuximab for metastatic colorectal cancer N Engl J Med 361 2009 96 97
13. DG Haller, JV Cox Provisional clinical opinion J Clin Oncol 27 2009 1925
14. MK Parmar, V Torri, L Stewart Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 1998 2815 2834 (Pubitemid 28562978)
15. R DerSimonian, N Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188 (Pubitemid 17189972)
16. DG Altman, JM Bland Interaction revisited: the difference between two estimates BMJ 326 2003 219 (Pubitemid 36143396)
17. GP Browman, L Cronin Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials Semin Oncol 21 1994 311 319 (Pubitemid 24191590)
18. RJ Simes Confronting publication bias: a cohort design for meta-analysis Stat Med 6 1987 11 29 (Pubitemid 17017356)
19. WG Cochran The combination of estimates from different experiments Biometrics 10 1954 101 129
20. RG Amado, M Wolf, M Peeters et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
21. C Bokemeyer, I Bondarenko, A Makhson et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671
22. J Douillard, S Siena, J Cassidy et al. Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): The PRIME trial Eur J Cancer 7 S6 2009 suppl; abstract 10LBA.
23. CS Karapetis, S Khambata-Ford, DJ Jonker et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
24. C Langer, J Kopit, M Awad et al. Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving cetuximab in combination with irinotecan: Results from the EPIC trial Ann Oncol 19 suppl 18 2008 VIII133
25. Maughan TS, Adams R, Smith CG, et al. Oxaliplatin and fluoropyrimidine chemotherapy plus or minus cetuximab: the effect of infusion 5-FU or capecitabine on the outcomes of the MRC COIN trial in advanced colorectal cancer (ACRC). Presented at: the American Society of Clinical Oncology Gastrointestinal Cancers Symposium March 26, 2010. Abstract 402.
26. Peeters M, Price T, Hotko Y, et al. Randomized phase III study of panitumumab with FOLFIRI versus FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer: patient-reported outcomes (PRO). Presented at: the American Society of Clinical Oncology Gastrointestinal Cancers Symposium March 26, 2010. Abstract 282.
27. E Van Cutsem, CH Kohne, E Hitre et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
28. JR Hecht, E Mitchell, T Chidiac et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 2009 672 680
29. J Tol, M Koopman, A Cats et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 2009 563 572
30. Q Pan, W Pao, M Ladanyi Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas J Mol Diagn 7 2005 396 403 (Pubitemid 41149655)
31. JH Van Krieken, A Jung, T Kirchner et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program Virchows Arch 453 2008 417 431
32. H Van Krieken, J Tol Setting future standards for KRAS testing in colorectal cancer Pharmacogenomics 10 2009 1 3
33. F Ciardiello, G Tortora EGFR antagonists in cancer treatment N Engl J Med 358 2008 1160 1174
34. J Mendelsohn, J Baselga Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol 21 2003 2787 2799 (Pubitemid 46606324)
35. CL Arteaga The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia J Clin Oncol 19 suppl 2001 32S 40S (Pubitemid 32880077)
36. M Moroni, S Veronese, S Benvenuti et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study Lancet Oncol 6 2005 279 286 (Pubitemid 40590264)
37. Z Tsuchihashi, S Khambata-Ford, N Hanna et al. Responsiveness to cetuximab without mutations in EGFR N Engl J Med 353 2005 208 209 (Pubitemid 41058356)
38. A Bardelli, S Siena Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer J Clin Oncol 28 2010 1254 1261
39. U McDermott, DB Longley, PG Johnston Molecular and biochemical markers in colorectal cancer Ann Oncol 13 suppl 4 2002 235 245 (Pubitemid 35363779)
40. M Frattini, D Balestra, S Suardi et al. Different genetic features associated with colon and rectal carcinogenesis Clin Cancer Res 10 2004 4015 4021 (Pubitemid 38812476)
41. H Linardou, IJ Dahabreh, D Kanaloupiti et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Lancet Oncol 9 2008 962 972
42. C Vale, J Tierney, A Meade et al. Effect of K-ras status on the effects of EGFR-targeted monoclonal antibody (Mab) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs) J Clin Oncol 27 15 suppl 2009 198s (abstract 4122).
43. Van Cutsem E, Rougier P, Kohne CH, et al. A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients)pts) with metastatic colorectal cancer (mCRC): results according to KRAS and BRAF mutation status. Presented at: the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO) 2009. Abstract P-6077.
44. EM Ibrahim, JM Zekri, BM Bin Sadiq Cetuximab-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-ras mutations Int J Colorectal Dis 2010
45. AP Venook, CD Blanke, D Niedzwiecki et al. Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma Clin Colorectal Cancer 6 2007 536 538 (Pubitemid 46918161)
46. Gold P, Shields A, Grothey A, et al. Phase III randomized study of irinotecan hydrochloride-based chemotherapy and cetuximab with versus without bevacizumab in patients with metastatic colorectal cancer that progressed on first-line therapy (treatment arm III closed to accrual as of 4/20/2009): Clinical Trials, 2007.
47. Shankaran V, Bentrem DJ, Mulcahy MF, et al. Economic implications of KRAS testing in metastatic colorectal cancer (mCRC). Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2009:Abstract 298.